Skip to main content

Table 2 Associations between hypermethylated and hypomethylated CpG sites and clinicopathological features

From: GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer

 

Post-op survival

Lymph node metastasis

Tumor size

Lauren classification

Metaplasia

Atrophy

H. pylori

CpgID/Gene promoter Hypermethylated in the tumor

       

 cg09350274/GFRA3

r = −0.69 p = 0.002

r = 0.52 p = 0.028

r = 0.48 p = 0.42

 

r = 0.480 p = 0.044

r = −0.590 p = 0.01

 

 cg02720618/ESR1

r = 0.56 p = 0.016

      

 cg04623837/HCG9

  

r = 0.64 p = 0.004

    

 cg07307078/TUBB6

  

r = 0.49 p = 0.04

    

 cg08615333/TGFB3

  

r = 0.5 p = 0.037

   

r = 0.504 p = 0.033

 cg01566170/CAPN2

   

r = −0.53 p = 0.023

 

r = 0.526 p = 0.025

 

 cg16986846/SCGB2A1

   

r = −0.576 p = 0.012

   

 cg02633817/FXYD3

    

r = −0.474 p = 0.047

  

 cg20640433/LAMA2

    

r = 524 p = 0.026

  

 cg21905630/GSH2

    

r = 0.52 p = 0.028

  

 cg13718960/RNASE1

     

r = 0.554 p = 0.017

 

 cg19118812/ELMO1

     

r = −0.546 p = 0.019

 

 cg26557658/FAM43B

     

r = −0.604 p = 0.008

 

 cg03616357/FLJ21159

      

r = 0.574 p = 0.013

 cg08615333/TGFB3

      

r = 0.504 p = 0.033

 cg14189571/ZFP42

      

r = 0.484 p = 0.042

 cg17872757/FLI1

      

r = 0.495 p = 0.037

 cg21790626/ZNF154

      

r = 0.573 p = 0.013

 cg27546237/COL4A1

      

r = 0.527 p = 0.025

CpgID/Gene promoter Hypomethylated in the tumor

       

 cg13694749/SCN4A

  

r = −0.638 p = 0.004

    

 cg18059088/HS3ST1

r = −0.474 p = 0.047

      

 cg26619317/CNN3

r = 0.481 p = 0.043

      

 cg07131544/NCR2

 

r = 0.496 p = 0.036

     

 cg14696870/FCER1A

   

r = −0.567 p = 0.014

   

 cg20676475/LCE3D

   

r = −0.708 p = 0.001

   

 cg00974864/FCGR3B

   

r = −562 p = 0.015

   

 cg13180098/RHO

   

r = −0.604 p = 0.008

r = −0.597 p = 0.009

r = 0.682 p = 0.002

 

 cg24691453/S100A4

   

r = 0.470 p = 0.49

   

 cg15309006/LOC63928

   

r = −0.499 p = 0.035

   

 cg26789453/TMEM116

   

r = −0.512 p = 0.030

   

 cg26264314/NALP5

   

r = −0.474 p = 0.047

   

 cg20383064/BFSP2

   

r = −0.487 p = 0.040

   

 cg25119415/MNDA

   

r = −0.646 p = 0.004

r = −0.514 p = 0.029

r = 0.547 p = 0.019

 

 cg14603345/BTBD3

    

p = −0.483 r = 0.042

  

 cg17356733/IFNGR2

     

r = −0.480 p = 0.044

 

 cg23756272/BCL2

     

r = −0.500 p = 0.035

 

 cg00842351/TJP2

     

r = −527 p = 0.24

 

 cg25248094/SH2D1A

     

r = 0.487 p = 0.041

r = −0.526 p = 0.025

 cg04454050/TREML1

      

0.474 0.047

 cg02611419/KCNK17

      

r = −502 p = 0.034

 cg05252264/FCAR

      

r = 0.587 p = 0.10

 cg22268164/TRHR

      

r = −0.619 p = 0.006

 cg02046017/LOC220070

      

r = 0.475 p = 0.046

 cg09191232/PAPSS1

      

r = −0.581 p = 0.011

  1. The filtered list of 100 hypermethylated and 100 hypomethylated CpG sites were compared to associated gene expression. 19 of the hypermethylated CpG sites and 25 of the hypomethylated CpG sites showed significant correlation with one or more of the clinicopathological parameters (Pearson correlation coefficients (r) and significance levels (p) are listed)